Semaglutide Reduces Alcohol Drinking in Mice and Rats by Modulating Brain GABA Signaling
Semaglutide dose-dependently reduced binge-like and dependence-induced alcohol drinking across two rodent species while enhancing GABA neurotransmission in brain regions controlling addiction, supporting clinical trials for alcohol use disorder.
Quick Facts
What This Study Found
Semaglutide demonstrated broad anti-alcohol effects across models and species:
- Dose-dependently reduced binge-like alcohol drinking in mice (drinking-in-the-dark model)
- Also reduced intake of other caloric/noncaloric solutions, suggesting a general reward-reducing effect
- Reduced binge-like and dependence-induced alcohol drinking in rats
- Effects observed in both male and female animals
Mechanistically, semaglutide increased spontaneous inhibitory postsynaptic current (sIPSC) frequency in central amygdala (CeA) and infralimbic cortex (ILC) neurons from alcohol-naive rats, indicating enhanced GABA release. However, this effect was absent in alcohol-dependent rats, suggesting chronic alcohol exposure may alter GLP-1 receptor-GABA interactions.
Key Numbers
How They Did This
Multiple rodent models were used: a drinking-in-the-dark procedure for binge-like drinking in male and female mice, and both binge-like and dependence-induced drinking models in male and female rats. Electrophysiology experiments measured spontaneous inhibitory postsynaptic currents (sIPSCs) in central amygdala and infralimbic cortex neurons from both alcohol-naive and alcohol-dependent rats after acute semaglutide application.
Why This Research Matters
Alcohol use disorder affects approximately 283 million people worldwide and has limited effective pharmacotherapies. Semaglutide is already widely available and well-characterized for safety, meaning it could potentially be repurposed for AUD much faster than developing an entirely new drug. The NIH/NIDA-affiliated research team behind this study and the growing anecdotal evidence from semaglutide users add momentum to clinical trials already underway.
The Bigger Picture
This study from George Koob's lab (former NIDA director) and Lorenzo Leggio's addiction research group provides foundational preclinical evidence for one of the most exciting emerging applications of GLP-1 drugs: treating addiction. The finding that semaglutide reduces not just alcohol but also other caloric/noncaloric rewards suggests it may broadly attenuate reward-seeking behavior through GLP-1 receptor signaling in brain addiction circuits. Clinical trials of GLP-1 drugs for AUD and other substance use disorders are now underway.
What This Study Doesn't Tell Us
All data is from rodent models, which don't fully replicate human drinking patterns or the complexity of alcohol use disorder. The GABA modulation effect was absent in alcohol-dependent rats, raising questions about efficacy in heavily dependent individuals. Semaglutide also reduced non-alcohol caloric intake, making it unclear whether the anti-alcohol effect is specific to alcohol reward or reflects a general reduction in consumption. Human clinical trial data is needed to confirm these findings.
Questions This Raises
- ?Will the anti-alcohol effects of semaglutide translate to reduced drinking in human clinical trials for alcohol use disorder?
- ?Why does semaglutide fail to modulate GABA transmission in alcohol-dependent rats — does this predict reduced efficacy in severe AUD patients?
- ?Is the reduction in alcohol intake a specific anti-reward effect or simply a secondary consequence of semaglutide's appetite-suppressing properties?
Trust & Context
- Key Stat:
- Alcohol reduction across multiple models and both species Semaglutide reduced alcohol consumption in every model tested — binge drinking in mice, binge drinking in rats, and dependence-induced drinking in rats — across both sexes, providing robust preclinical support for clinical trials.
- Evidence Grade:
- This is a rigorous preclinical study published in JCI Insight by a leading NIH addiction research team. The use of multiple species, both sexes, multiple drinking models, and a combination of behavioral and electrophysiological methods provides strong mechanistic evidence, though clinical translation awaits human trial data.
- Study Age:
- Published in 2023, this study is recent and highly relevant given the surge of interest in GLP-1 drugs for addiction treatment. Several clinical trials of semaglutide for alcohol use disorder are now underway, building directly on this preclinical evidence.
- Original Title:
- The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.
- Published In:
- JCI insight, 8(12) (2023)
- Authors:
- Chuong, Vicky, Farokhnia, Mehdi(8), Khom, Sophia, Pince, Claire L, Elvig, Sophie K, Vlkolinsky, Roman, Marchette, Renata Cn, Koob, George F, Roberto, Marisa, Vendruscolo, Leandro F, Leggio, Lorenzo
- Database ID:
- RPEP-06805
Evidence Hierarchy
Frequently Asked Questions
Why would a diabetes/weight loss drug reduce alcohol consumption?
GLP-1 receptors are found not just in the gut and pancreas but also in brain regions that control reward and motivation. Semaglutide appears to enhance GABA (inhibitory) signaling in the central amygdala and infralimbic cortex — areas that regulate compulsive behaviors and emotional responses to rewarding substances. By strengthening the brain's inhibitory circuits, semaglutide may reduce the rewarding effects of alcohol and other substances.
Can I use semaglutide to help me drink less?
While this animal study and anecdotal reports are promising, semaglutide is not approved for alcohol use disorder. Clinical trials are currently underway to test this application in humans. If you're concerned about your alcohol use, speak with your doctor about evidence-based treatments. If you're already on semaglutide and have noticed changes in your drinking habits, that's worth mentioning to your physician as well.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06805APA
Chuong, Vicky; Farokhnia, Mehdi; Khom, Sophia; Pince, Claire L; Elvig, Sophie K; Vlkolinsky, Roman; Marchette, Renata Cn; Koob, George F; Roberto, Marisa; Vendruscolo, Leandro F; Leggio, Lorenzo. (2023). The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.. JCI insight, 8(12). https://doi.org/10.1172/jci.insight.170671
MLA
Chuong, Vicky, et al. "The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.." JCI insight, 2023. https://doi.org/10.1172/jci.insight.170671
RethinkPeptides
RethinkPeptides Research Database. "The glucagon-like peptide-1 (GLP-1) analogue semaglutide red..." RPEP-06805. Retrieved from https://rethinkpeptides.com/research/chuong-2023-the-glucagonlike-peptide1-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.